List of Excipients in Branded Drug TRILIPIX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	TRILIPIX	fenofibric acid	0074-9642	FERRIC OXIDE RED
AbbVie Inc	TRILIPIX	fenofibric acid	0074-9642	FERRIC OXIDE YELLOW
AbbVie Inc	TRILIPIX	fenofibric acid	0074-9642	FERROSOFERRIC OXIDE
AbbVie Inc	TRILIPIX	fenofibric acid	0074-9642	GELATIN
AbbVie Inc	TRILIPIX	fenofibric acid	0074-9642	HYDROXYPROPYL CELLULOSE
AbbVie Inc	TRILIPIX	fenofibric acid	0074-9642	HYPROMELLOSE
AbbVie Inc	TRILIPIX	fenofibric acid	0074-9642	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

Trilipix Excipient Strategy and Commercial Opportunities for Fenofibric Acid

Last updated: September 9, 2026

Trilipix is the delayed-release capsule formulation of fenofibric acid, marketed for dyslipidemia and often used with statins. Its commercial value now lies less in branded exclusivity and more in generic manufacturing, differentiated release profiles, excipient substitution, fixed-dose combinations, and cost-efficient supply. The core formulation challenge is preserving fenofibric acid exposure while maintaining capsule performance, dissolution, stability, and compatibility with concurrent statin therapy.

What is Trilipix and which excipients does it contain?

Trilipix contains fenofibric acid in 45 mg and 135 mg delayed-release capsules. The product is administered once daily and may be taken without regard to meals, which creates a formulation requirement for consistent drug release across relevant gastrointestinal and fed-state conditions (U.S. Food and Drug Administration [FDA], 2012).

The FDA-approved labeling identifies the following inactive ingredients:

Excipient	Likely formulation role
Lactose monohydrate	Diluent and pellet or powder bulking agent
Crospovidone	Superdisintegrant and liquid-wicking aid
Hypromellose	Film former, binder, or release-controlling polymer
Sodium lauryl sulfate	Wetting agent and dissolution aid
Colloidal silicon dioxide	Glidant and moisture-flow aid
Magnesium stearate	Lubricant
Talc	Anti-adherent and coating aid
Titanium dioxide	Opacifier and colorant
Triacetin	Plasticizer for polymeric coating
Gelatin	Capsule-shell material
FD&C Blue No. 1	Capsule colorant

The precise function of each material depends on where it is used in the manufacturing process. In a multiparticulate delayed-release product, excipients may be present in the drug-containing core, seal coat, functional coating, capsule shell, or final blend. The public label does not disclose the quantitative composition or the exact location of every excipient within the dosage form (FDA, 2012).

Why is the formulation delayed release?

Delayed release can protect the active ingredient from premature release in the stomach and control delivery into the small intestine. A formulation using polymer-coated particles or pellets can also improve dose uniformity and enable capsule filling at two strengths.

Hypromellose, talc, titanium dioxide, triacetin, and related coating materials are consistent with a multiparticulate coating system. Triacetin is commonly used as a plasticizer to improve coating-film flexibility. Talc can reduce tack during coating. Sodium lauryl sulfate can improve wetting where the active ingredient or granules have poor aqueous dispersion.

The commercial objective is not simply to reproduce the inactive-ingredient list. An abbreviated new drug application applicant must demonstrate pharmaceutical equivalence and bioequivalence using its own formulation and manufacturing process. The applicant may use different excipients if the resulting product satisfies FDA requirements.

What excipient attributes matter most for generic Trilipix?

The highest-value excipient decisions concern release control, wetting, mechanical robustness, and reproducibility.

Release-control polymer

The polymer system must prevent premature release in acidic media and support rapid, complete release after the dosage form reaches intestinal conditions. Small changes in polymer grade, viscosity, particle size, coating weight gain, or plasticizer level can alter:

• Acid-stage resistance
• Intestinal-stage dissolution
• Lag time
• Drug-release rate
• Capsule-to-capsule variability
• Stability under elevated temperature and humidity

A generic manufacturer should treat the enteric or delayed-release coating as a critical material attribute rather than a replaceable commodity input.

Wetting and dissolution aids

Fenofibric acid is a lipophilic carboxylic acid with formulation behavior affected by pH, particle size, surface area, and wetting. Sodium lauryl sulfate can improve wetting and reduce dissolution variability, but excessive surfactant may affect granule strength, coating behavior, or gastrointestinal tolerability.

Potential alternatives include polysorbates, sodium docusate, poloxamers, or other compendial surfactants. Each substitution requires comparative dissolution and stability work. A lower-cost alternative is not commercially useful if it increases batch failure rates or produces a bioequivalence risk.

Filler and binder system

Lactose monohydrate provides bulk and supports capsule fill-weight control. It can be attractive from a cost and supply perspective, but lactose introduces considerations involving moisture, particle-size distribution, supplier variability, and patient labeling.

Microcrystalline cellulose, mannitol, or dibasic calcium phosphate could provide substitution routes. The choice depends on the manufacturing platform:

• Direct blending favors flowable, compressible materials.
• Pelletization favors controlled wetting and binder behavior.
• Drug layering requires consistent particle deposition and drying.
• Capsule filling requires stable bulk density and low segregation.

Lubricant and flow system

Magnesium stearate and colloidal silicon dioxide are conventional choices for lubrication and flow. Their levels require control because over-lubrication can reduce wetting and slow dissolution. Excess colloidal silicon dioxide can alter powder handling, increase dusting, and affect blend uniformity.

For a delayed-release product, flow and lubrication changes should be evaluated against dissolution, not only capsule-fill performance.

What is the commercial opportunity for excipient suppliers?

The excipient opportunity is mainly in qualified substitutions, functional coating systems, and supply-chain resilience. Trilipix is a mature product, so the market is price-sensitive and unlikely to support a premium excipient without a measurable manufacturing benefit.

Functional coating systems

A supplier that offers a prequalified enteric coating system can reduce development time for generic manufacturers. The strongest value proposition would include:

• Consistent polymer particle size
• Narrow viscosity variation
• Controlled plasticizer content
• Reliable acid resistance
• Rapid intestinal release
• Low coating weight gain
• Compatibility with aqueous processing

Ready-to-use coating dispersions may have an advantage over individual raw materials when they reduce process development and operator variability.

Low-moisture and robust processing grades

Suppliers can target grades that support high-throughput aqueous coating, fluid-bed processing, or dry granulation. Relevant performance claims include lower residual moisture, reduced agglomeration, improved flow, and consistent film formation.

Because fenofibric acid products may be manufactured in multiple markets, suppliers with dual-source or regional production can reduce interruption risk for generic manufacturers.

Lactose-free or low-allergen positioning

Lactose replacement is a secondary opportunity. A lactose-free version could address manufacturer preferences, labeling strategies, or portfolio standardization. It would not automatically create clinical differentiation. The substitute must maintain capsule fill, dissolution, stability, and bioequivalence without increasing cost materially.

Color and capsule-shell optimization

Titanium dioxide and synthetic colorants are subject to changing market preferences and regional regulatory scrutiny. A manufacturer may seek white, opaque, or color-free capsule-shell systems to simplify global registration. The commercial opportunity is strongest when the supplier can support multiple markets with the same shell platform.

What formulation patents protect Trilipix?

Trilipix’s historical protection included product and formulation patents associated with fenofibric acid delayed-release dosage forms. The relevant legal position must be evaluated through the FDA Orange Book, the underlying patent documents, and jurisdiction-specific litigation records rather than by relying solely on the commercial product label.

The key distinction is between:

Protection category	Relevance to Trilipix
Active-ingredient patents	Historically important, but generally weak for a mature product if expired
Delayed-release formulation patents	Potentially relevant to pellet structure, coating, release profile, or excipient combinations
Method-of-use patents	May cover treatment of dyslipidemia or coadministration with statins
Manufacturing patents	May create process barriers without blocking all alternative formulations
Regulatory exclusivity	Separate from patent protection and generally expired for this product

FDA approved Trilipix in 2008 under NDA 022224. Its five-year new chemical entity exclusivity period has expired. The product therefore does not have current NCE-based market protection. Any remaining patent risk would depend on listed patent status, claim scope, enforceability, and the design of a generic applicant’s product (FDA, Drugs@FDA, n.d.).

A formulation patent is commercially meaningful only if its claims cover the proposed generic’s actual composition or process. A competitor can sometimes avoid infringement by changing the polymer, coating sequence, particle architecture, or manufacturing conditions while maintaining equivalent clinical performance.

What is the Orange Book status of Trilipix?

Trilipix is a small-molecule prescription product, not a biologic. Biosimilar law therefore does not apply. Generic applicants use the ANDA pathway and may submit Paragraph IV certifications against unexpired listed patents.

The central regulatory questions are:

1. Whether any patents remain listed for the reference product.
2. Whether those patents cover the active ingredient, dosage form, strength, method of use, or manufacturing process.
3. Whether an ANDA applicant has submitted a Paragraph IV certification.
4. Whether the reference-product sponsor filed patent litigation within the statutory period.
5. Whether any litigation triggered a 30-month stay.
6. Whether settlement terms restrict launch timing or other commercial conduct.

The Orange Book must be checked by product name, NDA number, strength, and dosage form because patent listings and delisting events can change over time. A generic company should not assume that the absence of current branded promotion means the absence of historical litigation or residual patent risk (FDA, n.d.-a).

When did Trilipix lose exclusivity, and when did generic competition begin?

The main regulatory exclusivity period began with the 2008 approval and expired after the five-year NCE period. Generic competition subsequently developed through ANDA approvals for fenofibric acid delayed-release capsules.

Event	Approximate timing	Commercial effect
Trilipix FDA approval	December 2008	Launch of 45 mg and 135 mg delayed-release capsules
NCE exclusivity	Through approximately 2013	Blocked ANDA approval during the exclusivity period
Patent and regulatory review	2013 onward	Increased generic entry opportunity
Generic approvals and market entry	Mid-to-late 2010s	Price erosion and substitution
Mature generic market	2020s	Low brand leverage and contract-manufacturing opportunity

Exact launch timing differs by manufacturer, authorized-generic status, patent certifications, settlements, and commercial decisions. FDA approval of an ANDA does not guarantee immediate commercial launch.

Which companies are challenging or competing with Trilipix?

The competitive field includes manufacturers of fenofibric acid delayed-release capsules and manufacturers of alternative fibrate products. Relevant alternatives include fenofibrate tablets or capsules, gemfibrozil, and branded or generic combination lipid-lowering regimens.

Competitive pressure comes from four directions:

• Generic fenofibric acid delayed-release capsules
• Generic fenofibrate products
• Statin monotherapy or intensified statin therapy
• Combination treatment using statins with other lipid-lowering agents

The principal commercial distinction is dosing and formulation convenience. Fenofibric acid products are often used with statins, while gemfibrozil has clinically important interaction considerations with some statins. This can support continued prescribing of fenofibric acid despite generic price erosion.

What formulation opportunities exist for fenofibric acid?

Lower-cost delayed-release capsules

The most practical opportunity is a robust generic capsule using an alternative polymer or optimized coating process. The target is lower manufacturing cost without changes in dissolution or bioequivalence.

Fixed-dose combinations

A fixed-dose fenofibric acid and statin product could improve adherence and simplify therapy. Regulatory and commercial barriers are substantial:

• The combination must demonstrate the safety and effectiveness of both components.
• Drug-drug interaction data are required.
• Dose flexibility is reduced.
• Different titration needs may limit clinical adoption.
• Patent or exclusivity issues may attach to the statin component.

A fixed-dose combination is more attractive in markets where adherence, prescription simplicity, or reimbursement supports a premium.

Sprinkle or alternative oral dosage forms

A capsule that can be opened and sprinkled on soft food could address swallowing difficulties. This strategy requires comparative stability, dose-uniformity, food-mixing, and dissolution studies. Because the product is delayed release, the pellets must remain intact during administration.

Global capsule and excipient harmonization

A manufacturer supplying multiple regions could reduce cost by using one core formulation with limited market-specific changes. Colorants, titanium dioxide restrictions, capsule-shell requirements, and local excipient acceptance can complicate this strategy.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are more important than raw-material scarcity. The most sensitive operations are drug layering, pellet growth, polymer coating, drying, capsule filling, and dissolution control.

A technically strong generic process should control:

• Active content uniformity
• Pellet size distribution
• Coating thickness
• Acid-stage resistance
• Intestinal-stage release
• Residual solvent and moisture
• Capsule fill-weight variation
• Stability under accelerated conditions

Intellectual-property risk may arise from coating architecture, specific polymer combinations, particle-size specifications, or process parameters. A freedom-to-operate review should examine claim language, prosecution history, terminal disclaimers, expiration dates, and continuation patents. Process changes that avoid a composition claim may still implicate a manufacturing claim.

How strong is the Trilipix patent estate?

The estate is commercially weaker than it was at launch because regulatory exclusivity has expired and the product has entered generic competition. Residual strength depends on whether any formulation or method-of-use claims remain enforceable and whether those claims are broad enough to cover commercially practical alternatives.

Factor	Assessment
Active-ingredient exclusivity	Expired
NCE exclusivity	Expired
Generic substitution risk	High
Formulation design-around potential	Generally meaningful
Biosimilar risk	Not applicable
Manufacturing barrier	Moderate
Brand pricing power	Limited
Excipient differentiation opportunity	Moderate for suppliers, low for premium finished-product pricing

The strongest remaining commercial moat is likely process know-how, quality consistency, supply reliability, and customer-specific regulatory support rather than broad molecule-level exclusivity.

What revenue exposure and launch scenarios matter?

Trilipix revenue is exposed to generic substitution, payer preference, and the availability of lower-cost fibrates. A generic launch can produce rapid price compression, although supply shortages or limited manufacturer participation can temporarily support higher prices.

Launch scenario	Expected market effect
One generic entrant	Moderate price pressure; branded retention may remain
Several generic entrants	Rapid erosion in average selling price
Authorized generic or branded discounting	Slower branded volume decline but lower net price
Manufacturing shortage	Temporary price recovery or share volatility
Fixed-dose combination launch	Potential niche premium if adherence improves
Formulation failure or recall	Short-term share transfer to competitors

For an excipient supplier, the attractive target is not the branded revenue pool. It is the aggregate volume of generic manufacturers, contract development and manufacturing organizations, and regional licensees that require validated delayed-release platforms.

Key Takeaways

• Trilipix is fenofibric acid delayed-release capsules in 45 mg and 135 mg strengths.
• Its public label identifies lactose monohydrate, crospovidone, hypromellose, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate, talc, titanium dioxide, triacetin, gelatin, and FD&C Blue No. 1.
• The critical excipient function is consistent delayed release, wetting, coating integrity, powder flow, and capsule-fill reproducibility.
• The NCE exclusivity period has expired, and generic competition is established.
• The main commercial opportunity is generic formulation and excipient-platform supply, not premium branded positioning.
• Enteric or delayed-release coating systems, robust processing grades, lactose alternatives, and global capsule-shell platforms offer the clearest excipient opportunities.
• Fenofibric acid is a small molecule, so biosimilar risk is not relevant.
• Paragraph IV exposure depends on current Orange Book listings and any surviving formulation or method-of-use patents.
• Fixed-dose combinations and sprinkle capsules are possible but require substantial regulatory and commercial validation.
• Manufacturing know-how and supply reliability are more defensible than molecule-level intellectual property.

FAQs

Is Trilipix the same as fenofibrate?

No. Trilipix contains fenofibric acid, the active metabolite of fenofibrate. Fenofibrate and fenofibric acid products have different dosage forms, strengths, labeling, and regulatory records.

Can lactose be removed from a generic Trilipix formulation?

Yes, a generic applicant may use a different excipient system if the product satisfies pharmaceutical-equivalence, bioequivalence, quality, and stability requirements. Lactose replacement can affect flow, moisture, dissolution, and capsule fill.

Does Trilipix require an enteric-coated capsule shell?

Not necessarily. Delayed release can be achieved through coated pellets, granules, or particles placed inside a conventional capsule shell. The dosage form’s release performance, rather than the shell alone, determines the regulatory outcome.

Is a fenofibric acid and statin combination commercially attractive?

It can be attractive where adherence and prescription simplification have value. The opportunity is limited by dose titration, interaction management, reimbursement, and the need to support the combination’s regulatory claims.

Are excipient changes in a generic Trilipix product automatically low risk?

No. Changes to polymer grade, surfactant level, lubricant concentration, or plasticizer content can change dissolution and bioavailability. Excipient substitutions require formulation development, comparative dissolution, stability testing, and regulatory justification.

References

1. U.S. Food and Drug Administration. (2012). Trilipix (fenofibric acid) delayed-release capsules: Prescribing information. AbbVie Inc.

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.-c). Abbreviated new drug application (ANDA) approvals. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products

5. DailyMed. (n.d.). Trilipix, fenofibric acid delayed-release capsules. National Library of Medicine. https://dailymed.nlm.nih.gov/